Cutler Group’s Trinity Biotech TRIB Stock Holding History

Cutler Group’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,400	Closed	-$58K	–	7321
2016 Q3	$58K	Buy	+2,400	New	+$149K	﹤0.01%	2318

Other funds holding TRIB

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Boston Partners

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Cutler Group's TRIB Position: Q4 2016 in Review

Cutler Group sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 100 shares — an estimated $3.44K sold.

Cutler Group first reported a position in TRIB in Q4 2015 and held it in 4 quarters. The position peaked at $7K in Q2 2016. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

Cutler Group reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
Cutler Group sold 100 Trinity Biotech shares in Q4 2016, an estimated $3.44K.
Cutler Group first reported a position in Trinity Biotech in Q4 2015 and held it in 4 quarters.
Cutler Group's Trinity Biotech position peaked at $7K in Q2 2016.
71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Cutler Group's 13F filing for Q4 2016, filed 12 Jan 2017.